Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCND3 | P30281 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020075 | 0.83 | NFE2L2 (0.62) | CA1NFE2L2MGLL | |
| SCHEMBL2020074 | 0.83 | NFE2L2 (0.62) | CA1NFE2L2MGLL | |
| SCHEMBL8821192 | 0.74 | NFE2L2 (0.76) | PTGS2NFE2L2 | |
| SCHEMBL16950533 | 0.72 | NFE2L2 (0.46) | ERN1PTGS2NFE2L2CES2BCHE | |
| SCHEMBL9419282 | 0.72 | NFE2L2 (0.46) | ERN1PTGS2NFE2L2CES2BCHE | |
| SCHEMBL17371178 | 0.72 | NFE2L2 (0.46) | ERN1PTGS2NFE2L2CES2BCHE | |
| SCHEMBL2095060 | 0.72 | NFE2L2 (0.46) | ERN1PTGS2NFE2L2CES2BCHE | |
| SCHEMBL2095062 | 0.72 | NFE2L2 (0.46) | ERN1PTGS2NFE2L2CES2BCHE | |
| SCHEMBL9419281 | 0.72 | NFE2L2 (0.46) | ERN1PTGS2NFE2L2CES2BCHE | |
| SCHEMBL3720665 | 0.72 | PTGS2 (0.42) | ERN1PTGS2NFE2L2CES2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858852-B1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | GILLIGAN MYRA | 2008-11-13 | — | — | US | disclosed |
| EP-1858852-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006095205-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | HTR2A, HTR2B, HTR2C | ERN1 4603/4885CA1 4624/4885PTGS2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.